Paolo Serra

Corrigendum to “Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma” [Respir. Med. 262, (2026), 109127]

Nicola Scichilone, Giulia Genduso, Diego Bagnasco, Alessandro Barone et autres

es, ar, it, us (code pays fourni par la source)

Adherence to inhaled treatment is associated with better disease control and quality of life in mild-to-moderate asthma

Nicola Scichilone, Giulia Genduso, Diego Bagnasco, Alessandro Barone et autres

es, ar, it, us (code pays fourni par la source)

A real-life evaluation of SNOT-22 domains in a cohort of CRSwNP patients treated with biologic therapies for 12 months

Giulia Costanzo, Andrea Ledda, Giada Sambugaro, Giuseppe Murdaca et autres

Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disorder associated with rhinorrhea, nasal obstruction, nasal congestion, hyposmia, anosmia, and facial pain or pressure for over 12 weeks. This study examines the Sino-Nasal Outcome Test 22 (SNOT-22) score and its relationship …

it (code pays fourni par la source)

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

Andrea Ledda, Giulia Costanzo, Giada Sambugaro, Cristiano Caruso et autres

BACKGROUND: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a "type 2" (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition …

it (code pays fourni par la source)

Multi-omics investigation on the prognostic and predictive factors in metastatic breast cancer using data from Phase III ribociclib clinical trials: A statistical and machine learning analysis plan

Thibaud Coroller, Berkman Sahiner, Anup Amatya, Alexej Gossmann et autres

A bstract In 2020, Novartis Pharmaceuticals Corporation and the U.S. Food and Drug Administration (FDA) started a 4-year scientific collaboration to find novel radiogenomics-based prognostic and predictive factors for HR+/HER2-metastatic breast cancer under a Research Collaboration Agreement. This manuscript aims to detail …

ch, cn, nz, us, th (code pays fourni par la source)

Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials

Yan Ji, Vitaly Yartsev, Michelle Quinlan, Paolo Serra et autres

BACKGROUND AND OBJECTIVE: Renal impairment is common in patients with cancer and can alter the PK and thus the safety and efficacy of drugs. We assessed the impact of renal impairment during treatment with ribociclib, a cyclin-dependent kinase 4/6 inhibitor, and determined …

ch, us (code pays fourni par la source)

EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA -mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).

Michelino De Laurentiis, Luís Costa, Joseph Gligorov, Ann Knop et autres

TPS1109 Background: Endocrine therapy (ET) + CDK4/6i is standard of care for HR+, HER2− ABC; however, CDK4/6i resistance, in which the phosphatidylinositol-3-kinase (PI3K) pathway has a key role, remains challenging. Progression-free survival (PFS) for ≥ 2nd-line ET monotherapy post CDK4/6i is poor; …

it, pt, fr, dk, pl, es, gb, ch, de (code pays fourni par la source)

Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer

Joyce O’Shaughnessy, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap et autres

Abstract Background: MONALEESA-2 (ML-2) recently reported a statistically significant overall survival (OS) benefit with first-line ribociclib (RIB) + letrozole (LET) over placebo (PBO) + LET in postmenopausal patients with HR+/HER2- advanced breast cancer (ABC) (median, 63.9 vs 51.4 months; hazard ratio, 0.76; …

us, il, sg, nl, fr, cz, de, it, gb, ch (code pays fourni par la source)

Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation

Lucrezia Ferrario, Fabrizio Schettini, Elisabetta Garagiola, A Cecchi et autres

Lucrezia Ferrario,1 Fabrizio Schettini,1 Elisabetta Garagiola,1 Adriana Cecchi,2 Lucia Lugoboni,3 Paolo Serra,4 Emanuele Porazzi,1 Emanuela Foglia1 1Carlo Cattaneo – LIUC University and LIUC Business School, Castellanza, Italy; 2ARCS – Azienda Regionale di Coordinamento per la Salute, Udine, Italy; 3Bee Care, Lugano, Switzerland; …

Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation

Lucrezia Ferrario, Fabrizio Schettini, Elisabetta Garagiola, A Cecchi et autres

Purpose: To evaluate the incremental benefits concerning the implementation of closed-system medical devices for the preparation and administration of chemotherapy agents (integrated or not with traceable workflow), within an Italian clinical practice, in which the use of such technologies is not standardized. …

it (code pays fourni par la source)

Integrative assessment of the effect of renal function on ribociclib treatment and dose recommendation in advanced breast cancer patients.

Yan Ji, Vitaly Yartsev, Yingbo Wang, Michelle Quinlan et autres

e13037 Background: Ribociclib is an orally administered CDK4/6 inhibitor used in combination with endocrine therapy (ET) to treat women with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative advanced breast cancer (ABC). An integrative assessment was conducted to evaluate the effect of …

ch, us (code pays fourni par la source)

Performance of the Durata implantable cardioverter defibrillator lead: results of an independent multicenter study

Roberto Rordorf, Erika Taravelli, Giovanni B. Forleo, G. Giannola et autres

AIMS: The high rate of implantable cardioverter defibrillator (ICD) lead failures related to the Sprint Fidelis' and Riata's design have raised serious concerns about the reliability of ICD leads. The St. Jude Medical Durata family of leads replaced the preceding Riata line …

it, lb (code pays fourni par la source)